Druckversion von: http://www.www.dife.de/forschung/abteilungen/projektdetail.php?id=259&abt=EPI
Stand: 21.10.2018 19:26:59
Research has been continued into metabolically active metabolites predominantly generated by fat tissue in respect to lifestyle determinants and health consequences. C-reactive protein (CRP), interleukin 6, fetuin A, adiponectin, leptin, omentin, and neopterin have been investigated in collaboration with the Research Group Molecular Epidemiology of the Max Delbrück Center in relation to colon and liver cancer. Further metabolites will be investigated for their individual stability, relation to lifestyle determinants, and risk of chronic diseases, partly in collaboration with the Department of Molecular Epidemiology .
Investigations into metabolites from metabolomics platforms were first conducted within the case-cohort population of the Potsdam EPIC Study with type 2 diabetes and cardiovascular diseases as endpoints using the IDQ p150-Kit (Biocrates Life Sciences). The investigations of the metabolites included their reliability over time, their relations to lifestyle factors and anthropometric measures, e. g. hip circumference and weight gain, and to hypertension and other disease endpoints. Our investigations on diet-metabolite relations have been supplemented by work conducted at the Department of Molecular Epidemiology. The metabolites were also analyzed regarding their biological networks and seem to cluster primarily according to chemical classes, and to up- and downstream relations. Innovative statistical method- ology applied in the former studies included Gaussian graphical modeling for network analysis and Random Survival Forest for selection of variables. Together with the EPIC Study in Heidelberg, the set of metabolites will also be explored for their relation to cancer sites.
“Untargeted“ metabolomic profiles are available from EU projects and will also be exploited for their relation to diet and lifestyle factors.
© 2018 DIfE - Deutsches Institut für Ernährungsforschung. Alle Rechte vorbehalten. // Stand 29.03.2018